These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

348 related articles for article (PubMed ID: 27903663)

  • 21. Pulmonary Arterial Hypertension in Women.
    Memon HA; Park MH
    Methodist Debakey Cardiovasc J; 2017; 13(4):224-237. PubMed ID: 29744015
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pathobiology of pulmonary arterial hypertension: understanding the roads less travelled.
    Hemnes AR; Humbert M
    Eur Respir Rev; 2017 Dec; 26(146):. PubMed ID: 29263173
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Impact of pharmacologic interventions--treating endothelial dysfunction and group 2 pulmonary hypertension.
    Guazzi M; Gomberg-Maitland M; Naeije R
    Prog Cardiovasc Dis; 2015; 57(5):473-9. PubMed ID: 25446553
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treat-to-target approach in pulmonary arterial hypertension: a consensus-based proposal.
    Sitbon O; Baloira Villar A; Bauer F; Ekmehag B; Gin-Sing W; Jansson K; Kiely DG; Leuchte H; Manes A; Rosenkranz S; Escribano P
    Eur Respir Rev; 2012 Sep; 21(125):259-62. PubMed ID: 22941892
    [No Abstract]   [Full Text] [Related]  

  • 25. A paradigm shift in pulmonary arterial hypertension management.
    Rubin LJ; Galiè N; Simonneau G; McLaughlin V
    Eur Respir Rev; 2013 Dec; 22(130):423-6. PubMed ID: 24293459
    [No Abstract]   [Full Text] [Related]  

  • 26. An evidence-based approach to the management of pulmonary arterial hypertension.
    Archer SL; Michelakis ED
    Curr Opin Cardiol; 2006 Jul; 21(4):385-92. PubMed ID: 16755209
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Modern treatment to reduce pulmonary arterial pressure in pulmonary arterial hypertension.
    Akagi S; Matsubara H; Nakamura K; Ito H
    J Cardiol; 2018 Dec; 72(6):466-472. PubMed ID: 29898864
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Investigational pharmacotherapy and immunotherapy of pulmonary arterial hypertension: An update.
    Yang Y; Lin F; Xiao Z; Sun B; Wei Z; Liu B; Xue L; Xiong C
    Biomed Pharmacother; 2020 Sep; 129():110355. PubMed ID: 32559622
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Management of Severe Portopulmonary Hypertension With Dual Oral Therapy Before Liver Transplantation.
    Vionnet J; Yerly P; Aubert JD; Pascual M; Aldenkortt F; Berney T; Giostra E; Moradpour D; Schiffer E
    Transplantation; 2018 May; 102(5):e194. PubMed ID: 29485510
    [No Abstract]   [Full Text] [Related]  

  • 30. Acute hemodynamic effects of single oral dose of bosentan in patients with pulmonary arterial hypertension related to congenital heart disease.
    Ajami G; Ahmadipour M; Amoozgar H; Bourzoee M; Cheriki S; Shakiba AM; Edraki MR
    Congenit Heart Dis; 2014; 9(4):343-8. PubMed ID: 25247216
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Inhaled iloprost plus oral sildenafil in patients with severe pulmonary arterial hypertension delays the need for lung transplantation.
    Lopez-Meseguer M; Berastegui C; Monforte V; Bravo C; Domingo E; Roman A
    Transplant Proc; 2013; 45(6):2347-50. PubMed ID: 23953548
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pulmonary arterial hypertension specific therapy: The old and the new.
    Zolty R
    Pharmacol Ther; 2020 Oct; 214():107576. PubMed ID: 32417272
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Sildenafil dosed concomitantly with bosentan for adult pulmonary arterial hypertension in a randomized controlled trial.
    Vizza CD; Jansa P; Teal S; Dombi T; Zhou D
    BMC Cardiovasc Disord; 2017 Sep; 17(1):239. PubMed ID: 28874133
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Treatment of pulmonary arterial hypertension with targeted therapies.
    O'Callaghan DS; Savale L; Montani D; Jaïs X; Sitbon O; Simonneau G; Humbert M
    Nat Rev Cardiol; 2011 Jul; 8(9):526-38. PubMed ID: 21769113
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Endothelin antagonism in pulmonary arterial hypertension.
    Lee SH; Channick RN
    Semin Respir Crit Care Med; 2005 Aug; 26(4):402-8. PubMed ID: 16121317
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pulmonary hypertension in 2012: contemporary issues in diagnosis and management.
    Lau EM; Corte TJ
    Panminerva Med; 2012 Mar; 54(1):11-28. PubMed ID: 22278113
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Interpreting risk reduction in clinical trials for pulmonary arterial hypertension.
    Lajoie AC; Bonnet S; Lacasse Y; Lega JC; Provencher S
    Eur Respir Rev; 2018 Jun; 27(148):. PubMed ID: 29769296
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Endothelin-1 receptor antagonists in fetal development and pulmonary arterial hypertension.
    de Raaf MA; Beekhuijzen M; Guignabert C; Vonk Noordegraaf A; Bogaard HJ
    Reprod Toxicol; 2015 Aug; 56():45-51. PubMed ID: 26111581
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacological therapy for patients with chronic thromboembolic pulmonary hypertension.
    Hoeper MM
    Eur Respir Rev; 2015 Jun; 24(136):272-82. PubMed ID: 26028639
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Early combination of pulmonary vasodilators prevents chronic kidney disease progression in connective tissue disease-associated pulmonary hypertension.
    Hanaoka H; Ishigaki S; Takei H; Hiramoto K; Saito S; Kondo Y; Kikuchi J; Kaneko Y; Takeuchi T
    Int J Rheum Dis; 2021 Nov; 24(11):1419-1426. PubMed ID: 34626090
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.